Stoke Therapeutics, Inc. (STOK) — closed signal from December 16, 2025
Target reached Published before the outcome was known, scored automatically when the window closed on March 16, 2026.
Predicted vs. what happened
What happened
Reached its target in 76 days.
The thesis — published December 16, 2025
Investors may keep bidding the stock higher for the next few months after strong long-term trial results for zorevunersen with Biogen and a big after-hours price jump. The short-term picture looks positive, but because trading is light the price can jump or drop quickly, so prefer buying on small pullbacks and keep position sizes modest.
Primary drivers
- Strong long-term trial results with Biogen that can sustain interest for weeks
- Positive short-term price action that may continue if pullbacks stay calm
- Small available shares and low trading can magnify moves up or down
- Insider option exercise increased shares for sale, a short-term supply risk
How it played out
STOK: target reached in 76 days
Lyra published STOK at $33.13 on 2025-12-16 with 20% expected growth. The thesis pointed to long-term zorevunersen trial results with Biogen, positive short-term price action, small available shares and light trading that could magnify moves, and an insider option exercise as a short-term supply risk.
Inside the window, STOK reached a peak of $40.22 on 2026-03-10, above the $39.76 target. The peak gain was 21.4%, and the target was reached in 76 days. The stock ended the window at $33.96. The thesis played out, though the final price had fallen back near the publication price.
Prices are shown split- and dividend-adjusted, matching what public charts show today.
Share this receipt
A scored call, published before the outcome was known. Paste the link anywhere — it unfurls as the card above.
Read the next call before it closes.
This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.